Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2022 Nov;82(16):1591-1602. doi: 10.1007/s40265-022-01778-0. Epub 2022 Nov 14.
Empagliflozin (Jardiance), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) initially developed to treat type 2 diabetes mellitus (T2DM), has also been approved in the EU and USA for the treatment of all adults with symptomatic chronic heart failure (CHF), regardless of their left ventricular ejection fraction (LVEF). In pivotal phase III trials in ambulant patients with symptomatic CHF and mildly-reduced or preserved ejection fraction (EMPEROR-Preserved; LVEF > 40%) or those with symptomatic CHF and reduced ejection fraction (EMPEROR-Reduced; LVEF ≤ 40%), the addition of oral empagliflozin 10 mg/day to standard of care significantly reduced the risk of cardiovascular (CV) death or hospitalization for HF (HHF), as well as that of a number of other outcomes indicative of worsening HF, compared with placebo. The beneficial effect of empagliflozin on CV death/HHF was seen irrespective of the presence or absence of T2DM and regardless of background HF therapies. In addition, empagliflozin significantly improved health-related quality of life (HRQOL) and was generally well tolerated, with an adverse event profile that was generally consistent with that seen in patients with T2DM. Thus, empagliflozin is a valuable treatment option for ambulant patients with symptomatic CHF across a broad LVEF spectrum.
恩格列净（Jardiance），一种钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i），最初开发用于治疗 2 型糖尿病（T2DM），已在欧盟和美国获得批准，用于治疗所有有症状的慢性心力衰竭（CHF）成人，无论其左心室射血分数（LVEF）如何。在有症状的 CHF 且射血分数轻度降低或保留（EMPEROR-Preserved；LVEF>40%）或有症状的 CHF 且射血分数降低（EMPEROR-Reduced；LVEF≤40%）的门诊患者的关键 III 期试验中，与安慰剂相比，每天口服恩格列净 10mg 可显著降低心血管（CV）死亡或因心力衰竭（HHF）住院的风险，以及其他一些表明 HF 恶化的结局的风险。无论是否存在 T2DM 以及是否存在背景 HF 治疗，恩格列净对 CV 死亡/HHF 的有益作用都可见。此外，恩格列净显著改善了健康相关生活质量（HRQOL），并且通常耐受良好，其不良事件谱与 T2DM 患者所见的不良事件谱一致。因此，对于射血分数广泛的有症状的 CHF 门诊患者，恩格列净是一种有价值的治疗选择。
